Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rectal dexmedetomidine
- Development stage
- Unknown
- Lead developer
- Assiut University
- Modality
- Small Molecules
- Administration
- Rectal
01
Overview
DEX-Rectal is a plain rectal suppository formulation of dexmedetomidine, a selective alpha-2 adrenergic receptor agonist. It is being evaluated by Assiut University in a Phase 2/3 clinical trial (NCT05340725) as an active comparator against rectal dexmedetomidine niosomes (DEX-Nano-Rectal) and intravenous dexmedetomidine (DEX-IV) for postoperative analgesia in pediatric cancer patients undergoing bone marrow biopsy and aspiration procedures.
- Other names
- DEX-Rectaldexmedetomidine rectalrectal dexmedetomidine
02
Targets
ADRA2A (α2A)ADRA2B (α2B)ADRA2C (α2C)ADRA1A (α1A)
Beyond the preview
Go deeper on rectal dexmedetomidine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rectal dexmedetomidine.